Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Nov 11, 2019 8:29am
39 Views
Post# 30334791

RE:nr : more pbi data....

RE:nr : more pbi data.... What an imbecile. Riplazym? It's Ryplazim if you did any reading on websites or press releases. Did you do any due diligence other than read the misspelled posts of Pandorum/ Moneyman/Realstocky/Newcamo or you're just another clone of the SAME DUMBA$$ who can't learn to spell so he gives himself away every time. Wow, this stupidity goes deep.

marcjohnson wrote:

This and riplazim will push the sp somewhere between 50$-100$ in the next 12-18 months... im happy i bought a load of shares. And thanks for the welcome.  Now i want to see nasdaq news....

Liminal Biosciences Presents New Preclinical Data at ASN Kidney Week 2019

Canada NewsWire

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 11, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (TSX: LMNL) (OTCQX: PFSCF) ("Liminal BioSciences" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the Company and its' collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology's ("ASN") Kidney Week 2019 taking place from November 5-10, 2019 in Washington, DC.

"We believe that free fatty acid receptors represent promising targets for the development of small molecules in the treatment of inflammatory and fibrosis-related kidney diseases, and our preclinical efforts presented at Kidney Week 2019 continue to support our continued development in kidney disease" stated Kenneth Galbraith, Chief Executive Officer. "We look forward to reporting further progress in this therapeutic category as we nominate a drug candidate from our small molecule compound library to continue our development efforts."

The Company made two oral presentations focused on fatty acid receptors GPR40/GPR84 as promising targets in kidney fibrosis and a novel preclinical compound, PBI-4610, discovered by Liminal.

Key data was also presented at the conference in a poster presentation entitled:

  • PBI-4050 Reduces Renal Injury in a Mouse Model of Aristolochic Acid-Induced Nephropathy

A copy of this scientific poster is available from the Company's website at www.liminalbiosciences.com.

About Liminal BioSciences Inc.

Liminal BioSciences (www.liminalbiosciences.com) is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. Liminal BioSciences' research involves the study of several G-protein-coupled-receptors, GPR40, GPR84 and GPR120, known as free fatty acid receptors (FFAR's). These drug candidates have a novel mechanism of action as agonist ("stimulator") of GPR40 and GPR 120, and antagonist ("inhibitor") of GPR84. Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alstrm Syndrome after further consultation and approval by the FDA and EMA. A second drug candidate, PBI-4547, is currently in a Phase 1 clinical study.


 



<< Previous
Bullboard Posts
Next >>